Lys345

Site Information
yLAPPRRkGsQItQQ SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 10837169

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 3 , 4 , 5 , 6 )
Relevant cell line - cell type - tissue:	HEp-2 (squamous) ( 1 ) , Jurkat (T lymphocyte) ( 1 , 3 , 5 ) , U266 (plasma cell) ( 6 )

References
1	Akimov V, et al. (2018) UbiSite approach for comprehensive mapping of lysine and N-terminal ubiquitination sites. Nat Struct Mol Biol 25, 631-640 29967540 Curated Info
2	Lumpkin RJ, et al. (2017) Site-specific identification and quantitation of endogenous SUMO modifications under native conditions. Nat Commun 8, 1171 29079793 Curated Info
3	Udeshi ND, et al. (2013) Refined preparation and use of anti-diglycine remnant (K-ε-GG) antibody enables routine quantification of 10,000s of ubiquitination sites in single proteomics experiments. Mol Cell Proteomics 12, 825-31 23266961 Curated Info
4	Kim W, et al. (2011) Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol Cell 44, 325-40 21906983 Curated Info
5	Possemato A (2009) CST Curation Set: 6939; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
6	Possemato A (2009) CST Curation Set: 6587; Year: 2009; Biosample/Treatment: cell line, U266/MG132; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info